Short answer
REGENXBIO Inc. (RGNX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $30M (up 22.9% year over year) with net income of −$62M.
Q3 2025 key financials · XBRL
- Revenue
- $30M
- +22.9% YoY · +39.2% QoQ
- Net income
- −$62M
- −3.9% YoY · +12.6% QoQ
- Operating margin
- -176.3%
- EPS (diluted)
- −$1.20
- −1.7% YoY · +13.0% QoQ
Source: XBRL data from the REGENXBIO Inc. (RGNX) Q3 2025 10-Q on SEC EDGAR. USD.
REGENXBIO Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk Factors section not provided in submitted text
- No material-change disclosure available for comparison with the most recent 10-K
- Regulatory, legal, operational, competitive, and financial risks not stated
- CFO Rule 10b5-1 plan adopted August 12, 2025, covering sale of 156,401 securities by August 11, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other REGENXBIO Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.